COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE

被引：1
|
作者：
Kousoulakou, H. [1 ]
Kalogeropoulou, M. [2 ]
Panitti, E. [2 ]
机构：
[1] Univ Peloponnese, Corinth, Greece
[2] Novartis Hellas, Metamorfosis, Greece
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2101
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB62
引用
收藏
页码：A608 / A608
页数：1
相关论文
共 50 条
  • [1] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Hara Kousoulakou
    Magdalini Hatzikou
    Varvara Baroutsou
    John Yfantopoulos
    Cost Effectiveness and Resource Allocation, 15
  • [2] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Kousoulakou, Hara
    Hatzikou, Magdalini
    Baroutsou, Varvara
    Yfantopoulos, John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [3] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [4] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [5] ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE
    Hatzikou, M.
    Rombopoulos, G.
    Yfantopoulos, J.
    VALUE IN HEALTH, 2012, 15 (07) : A501 - A501
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [7] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [8] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
    Neslusan, Cheryl
    Martin, Silas
    Teschemaker, Anna
    Vo, Lien
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A309 - A310
  • [9] COST-EFFECTIVENESS OF ADD-ON THERAPIES TO METFORMIN: THE IMPACT OF MEDICATION ADHERENCE FOR TYPE 2 DIABETES MELLITUS
    Ho, C. M.
    Yeh, T. H.
    Lai, Y. T.
    VALUE IN HEALTH, 2021, 24 : S80 - S80
  • [10] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
12345